James P. Evans, MD, PhD is lead author of a commentary about the potential of genomic medicine.
Weili Lin, PhD, has been appointed Director of the UNC Biomedical Research Imaging Center (BRIC).
UNC Lineberger member Kurt Ribisl, PhD, was part of the study's research team.
Sixty physicians at the University of North Carolina Hospitals are listed in the latest version of “America’s Top Doctors,” a compilation that is published annually by Castle Connolly Medical Ltd. Of those, 32 are members of UNC Lineberger Comprehensive Cancer Center or involved in UNC Cancer Care’s multidisciplinary programs.
Richard Goldberg, MD is physician-in-chief of the N.C. Cancer Hospital and UNC Lineberger associate director of clinical research.
When the U.S. Food and Drug Administration (FDA) proposed new rules restricting outdoor tobacco advertising near schools and playgrounds in 2009, the tobacco industry argued that such rules would lead to a near complete ban on tobacco advertising in urban areas. An article in the March 2011 issue of the American Journal of Preventive Medicine shows that the effect of these rules would be less severe on businesses than the industry contends.
The article discusses Bernard’s work with the UNC Palliative Care Program and the Supportive Care Consult Service and Clinic.
Anders was chosen for her work on breast cancer brain metastases. Hoadley was selected for her contributions to the analysis of glioblastomas.
The Henry family shares the story of brothers Collin and Patrick, both diagnosed with cancer and receiving care at the N.C. Cancer Hospital.
UNC Lineberger members are involved in over 20 active startups.
It's a gene called DOT1L, and if you don't have enough of the DOT1L enzyme, you could be at risk for some types of heart disease.
Interested in starting a regular exercise program and supporting a good cause?
University Cancer Research Fund Enables Innovative Solutions to Complex Problems
Kaposi sarcoma-associated herpesvirus produces a protein that blocks the cell's inflammatory response
C. elegans model shows how RAS oncogene switching determines a cell's fate
Researchers investigating a genetic mutation in brain cancer and leukemia patients have discovered how one cancer metabolite battles another normal metabolite to contribute cancer development. Helping the “good guys” win that battle could yield new approaches for treatment.